Clinical Study on external application of Tongbi Tuomin ointment in treatment of allergic rhinitis in children

注册号:

Registration number:

ITMCTR2200005658

最近更新日期:

Date of Last Refreshed on:

2022-02-23

注册时间:

Date of Registration:

2022-02-23

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

通鼻脱敏膏外用治疗小儿变应性鼻炎临床研究

Public title:

Clinical Study on external application of Tongbi Tuomin ointment in treatment of allergic rhinitis in children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

通鼻脱敏膏外用治疗小儿变应性鼻炎临床研究

Scientific title:

Clinical Study on external application of Tongbi Tuomin ointment in treatment of allergic rhinitis in children

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200056952 ; ChiMCTR2200005658

申请注册联系人:

薛岱昀

研究负责人:

赵霞

Applicant:

Xue Dai Yun

Study leader:

Zhao Xia

申请注册联系人电话:

Applicant telephone:

18851092069

研究负责人电话:

Study leader's telephone:

13915994006

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gydyxxxdy@126.com

研究负责人电子邮件:

Study leader's E-mail:

zhaoxiahy@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区汉中路155号

研究负责人通讯地址:

江苏省南京市秦淮区汉中路155号

Applicant address:

155 Hanzhong road, Qinhuai district, Nanjing, Jiangsu Province

Study leader's address:

155 Hanzhong road, Qinhuai district, Nanjing, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省南京市秦淮区汉中路155号

Applicant's institution:

155 Hanzhong road, Qinhuai district, Nanjing, Jiangsu Province

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021NL-227-02

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Ethics Committee of Nanjing University of Chinese Medicine Affiliated Hospital(Jiangsu Provincial Hospital of traditional Chinese medicine)

伦理委员会批准日期:

Date of approved by ethic committee:

2022/1/12 0:00:00

伦理委员会联系人:

王卯

Contact Name of the ethic committee:

Wang Mao

伦理委员会联系地址:

江苏省南京市秦淮区汉中路155号

Contact Address of the ethic committee:

155 Hanzhong road, Qinhuai district, Nanjing, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京中医药大学附属医院(江苏省中医院)

Primary sponsor:

Nanjing University of Chinese Medicine Affiliated Hospital(Jiangsu Provincial Hospital of traditional Chinese medicine)

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号

Primary sponsor's address:

155 Hanzhong road, Qinhuai district, Nanjing, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京中医药大学附属医院(江苏省中医院)

具体地址:

江苏省南京市秦淮区汉中路155号

Institution
hospital:

Nanjing University of Chinese Medicine Affiliated Hospital(Jiangsu Provincial Hospital of traditional Chinese medicine)

Address:

155 Hanzhong road, Qinhuai district, Nanjing, Jiangsu Province

经费或物资来源:

江苏省中医药领军人才培养项目

Source(s) of funding:

Training Program of leading talents of traditional Chinese medicine in Jiangsu Province

研究疾病:

儿童变应性鼻炎

研究疾病代码:

Target disease:

Allergic Rhinitis in children

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

非随机对照试验

Non randomized control

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

完成通鼻脱敏膏外用治疗小儿变应性鼻炎有效性、安全性评价;探索变应性鼻炎患儿与健康儿童代谢差异。

Objectives of Study:

To evaluate the efficacy and safety of Tongbi Tuomin ointment in the treatment of allergic rhinitis in children, and to explore the difference of metabolism between children with allergic rhinitis and healthy children.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)凡符合上述西医诊断标准者; (2)年龄在1~18岁之间,性别不限; (3)知情同意,志愿受试。获得知情同意书过程应符合GCP规定。

Inclusion criteria

(1) those who meet the above diagnostic criteria of western medicine; (2) those who are between 1 and 18 years of age and of any sex; (3) those who give informed consent and volunteer to be tested. The process of obtaining an informed consent shall be in accordance with the GCP.

排除标准:

(1)伴有严重并发症的患儿,如支气管哮喘发作、严重鼻息肉影响呼吸、鼻中隔偏曲明显以及睡眠呼吸暂停综合征需要手术治疗的患儿; (2)合并上呼吸道感染者; (3)合并心脑血管、肝肾和造血系统等原发性疾病患者; (4)正在接受脱敏治疗者; (5)对本中药成份过敏者; (6)本次变应性鼻炎发病1周内接受过相关药物治疗和手术者。 (7)正在参加其他药物临床试验的患者。

Exclusion criteria:

(1) children with severe complications, such as asthma attack, severe nasal polyp affecting breathing, significant deviated Septum, and sleep apnea syndrome requiring surgical treatment; (2) children with upper respiratory tract infection; (3) patients with primary diseases such as heart, brain, blood vessel, liver, kidney and hematopoiesis; (4) those who are undergoing desensitization treatment; (5) those who are allergic to the ingredients of this traditional Chinese medicine; (6) those who have received relevant drug treatment and surgery within one week of the onset of this allergic rhinitis. (7) patients participating in clinical trials of other drugs.

研究实施时间:

Study execute time:

From 2022-01-12

To      2023-12-31

征募观察对象时间:

Recruiting time:

From 2022-02-24

To      2023-12-31

干预措施:

Interventions:

组别:

空白组

样本量:

40

Group:

Blank Group

Sample size:

干预措施:

外用凡士林软膏

干预措施代码:

Intervention:

Vaseline ointment for external use

Intervention code:

组别:

外用组

样本量:

40

Group:

External Group

Sample size:

干预措施:

外用通鼻脱敏膏

干预措施代码:

Intervention:

Nasal desensitization ointment for external use

Intervention code:

组别:

口服组

样本量:

40

Group:

Oral Group

Sample size:

干预措施:

口服基本方中药汤剂

干预措施代码:

Intervention:

Take basic prescription decoction of traditional Chinese medicine

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京中医药大学附属医院(江苏省中医院)

单位级别:

三甲

Institution/hospital:

Nanjing University of Chinese Medicine Affiliated Hospital(Jiangsu Provincial Hospital of traditional Chinese medicine)

Level of the institution:

Grade A Class three

测量指标:

Outcomes:

指标中文名:

代谢组学产物

指标类型:

主要指标

Outcome:

Metabonomics product

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

鼻腔冲洗液

组织:

Sample Name:

Nasal irrigation

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 1
Min age years
最大 18
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机对照研究

Randomization Procedure (please state who generates the random number sequence and by what method):

Non randomized control trial

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2027年 发表论文

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2027 Publish papers

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究病历

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Medical records for trial

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above